James D’Rozario

1.8k total citations · 1 hit paper
25 papers, 872 citations indexed

About

James D’Rozario is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, James D’Rozario has authored 25 papers receiving a total of 872 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 13 papers in Genetics and 6 papers in Oncology. Recurrent topics in James D’Rozario's work include Chronic Lymphocytic Leukemia Research (9 papers), Chronic Myeloid Leukemia Treatments (6 papers) and Multiple Myeloma Research and Treatments (4 papers). James D’Rozario is often cited by papers focused on Chronic Lymphocytic Leukemia Research (9 papers), Chronic Myeloid Leukemia Treatments (6 papers) and Multiple Myeloma Research and Treatments (4 papers). James D’Rozario collaborates with scholars based in Australia, United Kingdom and United States. James D’Rozario's co-authors include Javier de la Serna, Tadeusz Robak, Michelle Boyer, Arnon P. Kater, Carolyn Owen, John F. Seymour, Marco Montillo, Yan Li, Ulrich Jaeger and Thomas J. Kipps and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

James D’Rozario

23 papers receiving 863 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

2018 595 citations John F. Seymour, James D’Rozario et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James D’Rozario Australia	10	565	399	259	212	199	25	872
Niki Stavroyianni Greece	18	448 0.8×	335 0.8×	177 0.7×	298 1.4×	192 1.0×	59	863
Georg Aue United States	16	615 1.1×	434 1.1×	267 1.0×	350 1.7×	240 1.2×	52	1.0k
Lisa Kujawski United States	13	359 0.6×	189 0.5×	255 1.0×	208 1.0×	313 1.6×	21	753
Sophie Gazzo France	16	448 0.8×	453 1.1×	136 0.5×	121 0.6×	266 1.3×	32	856
Kourong Miao China	17	342 0.6×	197 0.5×	202 0.8×	248 1.2×	560 2.8×	79	1.1k
Carsten Hirt Germany	18	433 0.8×	774 1.9×	120 0.5×	162 0.8×	181 0.9×	42	1.1k
Chun Qiao China	15	322 0.6×	179 0.4×	353 1.4×	224 1.1×	318 1.6×	100	825
Martha Glenn United States	15	250 0.4×	334 0.8×	220 0.8×	138 0.7×	206 1.0×	41	813
Adam S. Kittai United States	13	301 0.5×	252 0.6×	87 0.3×	157 0.7×	145 0.7×	79	690
Maria Verdugo United States	13	861 1.5×	599 1.5×	520 2.0×	246 1.2×	356 1.8×	27	1.2k

Countries citing papers authored by James D’Rozario

Since Specialization

Citations

This map shows the geographic impact of James D’Rozario's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James D’Rozario with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James D’Rozario more than expected).

Fields of papers citing papers by James D’Rozario

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James D’Rozario. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James D’Rozario. The network helps show where James D’Rozario may publish in the future.

Co-authorship network of co-authors of James D’Rozario

This figure shows the co-authorship network connecting the top 25 collaborators of James D’Rozario. A scholar is included among the top collaborators of James D’Rozario based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James D’Rozario. James D’Rozario is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Patel, Ronak, et al.. (2021). Alemtuzumab-Induced Red Cell Aplasia And Other Immune Cytopenias: Not So Â€˜Pureâ€™. Immunotherapy. 14(2). 95–99. 2 indexed citations

Quach, Hang, Masa Lasica, Anna Kalff, et al.. (2021). A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand.. Journal of Clinical Oncology. 39(15_suppl). TPS8055–TPS8055. 4 indexed citations

Mollee, Peter, John Reynolds, Wojciech Janowski, et al.. (2021). A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16). Blood. 138(Supplement 1). 2728–2728. 2 indexed citations

Kalff, Anna, Tiffany Khong, P. Joy Ho, et al.. (2021). Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14). Haematologica. 107(1). 321–325. 1 indexed citations

Mollee, Peter, John Reynolds, Wojciech Janowski, et al.. (2020). A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16). Blood. 136(Supplement 1). 4–5. 5 indexed citations

Harrup, Rosemary, Carolyn Owen, James D’Rozario, et al.. (2020). Efficacy of Subsequent Novel Targeted Therapies, Including Repeated Venetoclax-Rituximab (VenR), in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Previously Treated with Fixed-Duration Venr in the Murano Study. Blood. 136(Supplement 1). 44–45. 15 indexed citations

Coupland, Lucy A., Illa Téa, Thy T. Truong, et al.. (2019). GSTZ1 genotypes correlate with dichloroacetate pharmacokinetics and chronic side effects in multiple myeloma patients in a pilot phase 2 clinical trial. Pharmacology Research & Perspectives. 7(6). e00526–e00526. 15 indexed citations

D’Rozario, James, et al.. (2019). Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL. Therapeutic Advances in Hematology. 10. 153136473–153136473. 5 indexed citations

Choi, Philip, Sarah M. Hicks, Elizabeth E. Gardiner, et al.. (2019). Platelet Dysfunction Detected Using Rotational Thromboelastometry (ROTEM) in Severely Thrombocytopenic Patients with a Bleeding Phenotype. Blood. 134(Supplement_1). 2357–2357. 4 indexed citations

10.

Hiwase, Devendra, Peter Tan, James D’Rozario, et al.. (2018). Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study. Leukemia Research. 67. 109–115. 14 indexed citations

11.

D’Rozario, James, et al.. (2014). Pre infusion, post thaw CD34+ peripheral blood stem cell enumeration as a predictor of haematopoietic engraftment in autologous haematopoietic cell transplantation. Transfusion and Apheresis Science. 50(3). 443–450. 21 indexed citations

12.

Lickliter, Jason D., Kerry Taylor, Jeff Szer, et al.. (2014). An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial. Leukemia & lymphoma. 56(3). 630–638.

13.

Cummins, Katherine D., Stephen M. Jane, Robin Filshie, et al.. (2014). Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia. Blood Cancer Journal. 4(8). e237–e237. 6 indexed citations

14.

Subramaniam, Kavitha, Sanjiv Jain, M. Latimer, et al.. (2013). Two rare cases of Epstein–Barr virus‐associated lymphoproliferative disorders in inflammatory bowel disease patients on thiopurines and other immunosuppressive medications. Internal Medicine Journal. 43(12). 1339–1342. 11 indexed citations

15.

Subramaniam, Kavitha, James D’Rozario, & Paul Pavli. (2012). Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: A review. Journal of Gastroenterology and Hepatology. 28(1). 24–30. 69 indexed citations

16.

Lueck, Christian J., et al.. (2010). Reversible posterior encephalopathy syndrome associated with bortezomib. Internal Medicine Journal. 40(1). 69–71. 16 indexed citations

17.

Talaulikar, Girish, et al.. (2010). ACUTE INTERSTITIAL NEPHRITIS SECONDARY TO DEFERASIROX CAUSING ACUTE RENAL INJURY NEEDING SHORT-TERM DIALYSIS. Nephrology. 15(3). 377–377. 14 indexed citations

18.

Pasricha, Sant‐Rayn, Andrew Grigg, John Catalano, et al.. (2008). A multicenter phase 2 study of risk‐adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma. Cancer. 113(11). 3192–3198. 9 indexed citations

19.

Lickliter, Jason D., Chris Arthur, James D’Rozario, et al.. (2004). Phase II Pilot Study of Imatinib Mesylate Combined with Induction Chemotherapy in Blast-Phase CML and Ph+ ALL.. Blood. 104(11). 4682–4682. 1 indexed citations

20.

Scolyer, Richard A., et al.. (2000). Acute basophilic leukemia presenting with abnormal liver function tests and the absence of blast cells in the peripheral blood. Pathology. 32(1). 52–55. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact